ESR1 and breast carcinoma: For example, MammaPrint has a 70‐gene prognosis profile and was designed for selecting early (stage I‐II, ER+ or ER‐) breast cancer patients with low risk of developing metastasis, so that they could be spared adjuvant chemotherapy [41].